Vyome Holdings Inc

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 9 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.